These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6369888)

  • 21. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
    Lerner V; Miodownik C; Kaptsan A; Cohen H; Matar M; Loewenthal U; Kotler M
    Am J Psychiatry; 2001 Sep; 158(9):1511-4. PubMed ID: 11532741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders].
    Miodownik C; Cohen H; Kotler M; Lerner V
    Harefuah; 2003 Sep; 142(8-9):592-6, 647. PubMed ID: 14518160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo.
    Pacchetti C; Martignoni E; Bruggi P; Godi L; Aufdembrinke B; Miltenburger C; Voet B; Nappi G
    Mov Disord; 1993 Oct; 8(4):463-5. PubMed ID: 7901760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia.
    Alpert M; Friedhoff AJ; Diamond F
    Adv Neurol; 1983; 37():253-8. PubMed ID: 6134444
    [No Abstract]   [Full Text] [Related]  

  • 25. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management.
    Nasrallah HA; Dunner FJ; McCalley-Whitters M; Smith RE
    J Clin Psychiatry; 1986 Feb; 47(2):56-9. PubMed ID: 3003037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis.
    Davis KL; Berger PA
    Biol Psychiatry; 1978 Feb; 13(1):23-49. PubMed ID: 146524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG; Carter JH; Carlson NE
    Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial.
    Gerlach J; Thorsen K; Munkvad I
    Pharmakopsychiatr Neuropsychopharmakol; 1975 Mar; 8(2):51-6. PubMed ID: 788002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.
    Zhang XY; Zhou DF; Cao LY; Xu CQ; Chen DC; Wu GY
    J Clin Psychopharmacol; 2004 Feb; 24(1):83-6. PubMed ID: 14709952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-DOPA/carbidopa for nocturnal movement disorders in uremia.
    Walker SL; Fine A; Kryger MH
    Sleep; 1996 Apr; 19(3):214-8. PubMed ID: 8723378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effectiveness of piracetam in tardive dyskinesia - double-blind cross-over controlled trial with a placebo].
    Kabes J; Sikora J; Starý O; Pisvejc J; Hanzlícek L
    Cesk Psychiatr; 1983 Oct; 79(5):339-45. PubMed ID: 6357509
    [No Abstract]   [Full Text] [Related]  

  • 35. [Tardive dyskinesia: pergolid, a possible therapeutic option].
    Diehl A; Braus DF; Büchel C; Krumm B; Medori R; Gattaz WF
    Psychiatr Prax; 2003 Sep; 30(6):333-7. PubMed ID: 12970819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Utility of quetiapine in tardive dyskinesia].
    Navarro Pacheco BV; Montejo González AL; Martín Carrasco M
    Actas Esp Psiquiatr; 2003; 31(6):347-52. PubMed ID: 14639511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of tardive dyskinesia with propranolol.
    Schrodt GR; Wright JH; Simpson R; Moore DP; Chase S
    J Clin Psychiatry; 1982 Aug; 43(8):328-31. PubMed ID: 6124534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
    Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
    Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.